Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility
Journal of Cystic Fibrosis · 2024
DOI: 10.1016/j.jcf.2024.02.014 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Jaime L Rubin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Vertex Pharmaceuticals Incorporated, Boston, MA, United States. Electronic address: jaime_rubin@vrtx.com. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vertex Pharmaceuticals Incorporated, Boston, MA, United States. Electronic address: jaime_rubin@vrtx.com.
- Vertex Pharmaceuticals Incorporated, Boston, MA, United States. Electronic address: james_kreindler@vrtx.com.
Zitieren
APA
Rubin, J. L., & Kreindler, J. L. (2024). Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.02.014
Vancouver
Rubin JL, Kreindler JL. Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.02.014
BibTeX
@article{Rubin2024,
author = {Rubin, Jaime L and Kreindler, James L},
title = {Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility},
journal = {Journal of Cystic Fibrosis},
year = {2024},
doi = {10.1016/j.jcf.2024.02.014}
}
EUVIMED